- •Foreword
- •List of contributors
- •Preface
- •Dedication and Acknowledgments
- •Evolving knowledge in pharmacologic treatments
- •MEDICAL TREATMENT
- •VERTEPORFIN
- •ANTI-VEGF TREATMENT
- •OTHER MEDICAL TREATMENTS
- •“PLAYERS” IN OCULAR TREATMENT
- •THE DRUG
- •ROUTE OF ADMINISTRATION
- •Eye drops
- •Soluble ophthalmic drug inserts
- •Ion drug exchange
- •Intravitreal injections
- •Systemic administration
- •Sustained drug delivery system
- •Intraocular implants
- •Microparticles and nanoparticles
- •Liposomes
- •Encapsulated cell technology (ECT)
- •Iontophoresis
- •REFERENCES
- •SECTION 1: Basic Sciences in Retina
- •Retinal anatomy and pathology
- •INTRODUCTION
- •KEY CONCEPTS AND FUNDAMENTALS
- •NORMAL RETINAL ANATOMY
- •RETINAL PATHOLOGY
- •Congenital abnormalities
- •Dystrophies
- •Degenerations
- •Vascular diseases
- •Toxicities
- •Inflammatory diseases
- •Neoplasms
- •Retinal detachment
- •Trauma
- •Involvement of systemic diseases
- •SUMMARY AND KEY POINTS
- •REFERENCES
- •Retinal biochemistry, physiology, and cell biology
- •INTRODUCTION
- •VITREOUS BIOCHEMISTRY
- •VITREOUS DEGENERATION WITH AGING
- •PHYSIOLOGICAL AND PATHOLOGICAL CHANGES IN THE VITREORETINAL INTERFACE
- •BLOOD–RETINAL BARRIER
- •TIGHT JUNCTIONS
- •BLOOD–RETINA BARRIER DISRUPTION
- •MECHANISMS OF RETINAL ARTERIOLAR CALIBER CHANGES
- •MECHANISMS OF RETINAL VENULAR CALIBER CHANGES
- •MACULAR PIGMENTS
- •FUNCTIONS OF MACULAR PIGMENTS
- •Antioxidant
- •Optical filter
- •VISUAL CYCLE
- •RETINOID CYCLE
- •Outer segment of photoreceptors
- •Retinal pigment epithelium
- •Re-entry into the outer segment
- •Chaperones
- •PHOTOTRANSDUCTION
- •Activation
- •Inactivation
- •RETINAL PIGMENT EPITHELIUM AND LIPOFUSCIN
- •RETINAL PIGMENT EPITHELIUM
- •LIPOFUSCIN
- •Formation of lipofuscin
- •Lipofuscin and RPE atrophy
- •Stargardt’s disease and lipofuscin
- •Age-related macular degeneration and lipofuscin
- •MATRIX BIOLOGY
- •STRUCTURAL COMPOSITION OF THE BRUCH’S MEMBRANE
- •MACROSCOPIC CHANGES OF THE BRUCH’S MEMBRANE
- •CELL BIOLOGY OF BRUCH’S MEMBRANE
- •LIPID ACCUMULATION
- •MATRIX DYSREGULATION
- •MATRIX METALLOPROTEINASES
- •PHARMACOTHERAPY IMPLICATIONS
- •REFERENCES
- •INTRODUCTION
- •PROMOTERS OF ANGIOGENESIS
- •VEGF in physiologic and pathologic angiogenesis
- •Investigational approaches to VEGF inhibition in ocular neovascularization
- •RNA interference
- •Soluble VEGFR fusion protein: VEGF-Trap
- •Anecortave acetate
- •PLATELET-DERIVED GROWTH FACTOR
- •FIBROBLAST GROWTH FACTOR 2 (FGF2)
- •TUMOR NECROSIS FACTOR-α (TNF-α)
- •EPHS AND EPHRINS
- •NOTCH
- •ANGIOPOIETINS
- •Angiopoietin 1
- •Angiopoietin 2
- •ERYTHROPOIETIN
- •MATRIX METALLOPROTEINASES
- •INTEGRINS
- •COMPONENTS OF THE COMPLEMENT CASCADE
- •INHIBITORS OF ANGIOGENESIS
- •PIGMENT EPITHELIUM-DERIVED FACTOR
- •SOLUBLE VEGF RECEPTOR 1
- •VEGFXXXb ISOFORMS
- •COMPLEMENTARY REGULATORY PROTEIN C59
- •TRYPTOPHANYL-tRNA SYNTHASE FRAGMENT
- •OTHER INHIBITORS
- •SUMMARY
- •REFERENCES
- •Ocular immunity and inflammation
- •INTRODUCTION
- •HISTORY
- •KEY CONCEPTS AND FUNDAMENTALS IN MOLECULAR BIOLOGY AND BIOCHEMISTRY
- •INNATE IMMUNITY
- •ADAPTIVE IMMUNITY
- •MECHANISMS OF PATHOGENESIS
- •NONINFECTIOUS POSTERIOR AND PANUVEITIS
- •INFECTIOUS RETINITIS AND CHOROIDITIS
- •AGE-RELATED MACULAR DEGENERATION
- •DIABETIC RETINOPATHY
- •SUMMARY AND KEY POINTS
- •REFERENCES
- •INTRODUCTION
- •HISTORY
- •KEY CONCEPTS IN COMPLEMENT BIOLOGY
- •SUMMARY
- •REFERENCES
- •Genetics of retinal disease
- •INTRODUCTION
- •HISTORY OF RETINAL GENE DISCOVERY
- •KEY CONCEPTS AND FUNDAMENTS OF GENETIC METHODS IN THE STUDY OF RETINAL DISEASE
- •GENETICS: ILLUMINATING MECHANISMS OF PATHOGENESIS, REVEALING COMPLEXITY
- •RP: A “COMPLEX” MONOGENIC DISEASE
- •SHEDDING LIGHT ON AMD
- •DELIVERY OF GENES TO TARGET PATHOGENIC PATHWAYS
- •GENE-INDEPENDENT THERAPY
- •SUMMARY: THE FUTURE IS BRIGHT
- •REFERENCES
- •SECTION 2: Animal Models and Routes for Retinal Drug Delivery
- •Vitamins and supplements for age-related macular degeneration
- •INTRODUCTION
- •HISTORY
- •KEY CONCEPTS AND PHARMACOLOGY OF CURRENT DIETARY SUPPLEMENTS
- •EPIDEMIOLOGIC DATA OF ASSOCIATION OF FAT AND ω-3 LCPUFAs WITH AMD
- •AVAILABLE SUPPLEMENTS FOR MACULAR DEGENERATION
- •IMPLICATIONS OF RETINAL SUPPLEMENT PHARMACOLOGY
- •FUTURE DIRECTIONS: AREDS2
- •SUMMARY AND KEY POINTS
- •REFERENCES
- •Ocular pharmacokinetic, drug bioavailability, and intraocular drug delivery systems
- •INTRODUCTION
- •INTRAVITREAL ADMINISTRATION
- •OCULAR PHARMACOKINETICS
- •TOPICAL FORMULATIONS
- •CONVENTIONAL FORMULATIONS
- •INTRAOCULAR DRUG DELIVERY SYSTEMS
- •NONBIODEGRADABLE IMPLANTS
- •INTRAOCULAR BIODEGRADABLE DRUG DELIVERY SYSTEMS
- •ACKNOWLEDGMENTS
- •REFERENCES
- •INTRODUCTION
- •THE RATIONALE FOR INTRAVITREAL DRUG DELIVERY
- •HISTORY
- •KEY CONCEPTS AND FUNDAMENTAL POINTS IN RETINAL DRUG DELIVERY
- •STRATEGIES AND IMPLICATIONS FOR RETINAL PHARMACOTHERAPY
- •PREOPERATIVE PREPARATION
- •PROPHYLAXIS OF ENDOPHTHALMITIS: LOCAL DISINFECTION AND TOPICAL ANTIBIOTIC THERAPY
- •LOCAL TOPICAL ANESTHESIA
- •SURGICAL TECHNIQUES FOR RETINAL DRUG DELIVERY
- •THE PROCEDURE AND RECOMMENDED TECHNIQUE
- •COMPLICATIONS WITH THE ROUTE FOR DRUG DELIVERY
- •OCULAR COMPLICATIONS
- •PHARMACOKINETICS AND CLEARANCE OF INTRAVITREAL DRUGS
- •PHARMACOKINETICS OF INTRAVITREAL CRYSTALLINE TRIAMCINOLONE ACETONIDE
- •CLINICAL EXPERIENCE AND RESULTS IN VITRECTOMIZED, AIR-FILLED, OR SILICONE OIL EYES
- •VITRECTOMIZED EYES
- •Silicone oil tamponade
- •Gas tamponade
- •PREOPERATIVE DRUG APPLICATIONS
- •INTRAOPERATIVE DRUG APPLICATIONS
- •POSTOPERATIVE DRUG APPLICATIONS
- •SUMMARY AND KEY POINTS
- •REFERENCES
- •INTRODUCTION
- •HISTORY
- •KEY CONCEPTS
- •ANIMAL MODELS
- •DRUG DELIVERY MODALITIES
- •TOPICAL DRUG DELIVERY
- •TRANSSCLERAL DRUG DELIVERY
- •SUPRACHOROIDAL DRUG DELIVERY
- •INTRAVITREAL GAS-PHASE NANOPARTICLE DRUG DELIVERY
- •SUMMARY AND KEY POINTS
- •ACKNOWLEDGMENT
- •REFERENCES
- •INTRODUCTION
- •HISTORY
- •KEY CONCEPTS AND FUNDAMENTAL POINTS IN SUSTAINED-RELEASE DRUG DELIVERY
- •EXISTING SUSTAINED-RELEASE DRUG DEVICES
- •BIODEGRADABLE POLYMER IMPLANTS
- •LIPOSOME ENCAPSULATION
- •CELLULAR ENCAPSULATION
- •THE FUTURE
- •SUMMARY
- •ACKNOWLEDGMENT
- •REFERENCES
- •INTRODUCTION
- •PERMEATION BARRIERS AND ANATOMICAL CONSIDERATIONS
- •THEORETICAL BACKGROUND
- •CYCLODEXTRINS
- •ANIMAL TESTING OF ROUTES OF DRUG DELIVERY
- •SUMMARY AND KEY POINTS
- •REFERENCES
- •Thermo-sensitive hydrogels
- •INTRODUCTION
- •DELIVERY CHARACTERISTICS
- •POTENTIAL DELIVERY SITE
- •TOXICITY TESTING
- •FUTURE DIRECTION
- •SUMMARY AND KEY POINTS
- •REFERENCES
- •Retina and ocular toxicity to ocular application of drugs
- •INTRODUCTION
- •HISTORY
- •MAJOR CLASSES OF DRUGS AND THEIR SAFETY PROFILE AFTER LOCAL OCULAR APPLICATION FOR RETINA THERAPY
- •CORTICOSTEROIDS
- •ANTIBIOTICS
- •NONSTEROIDAL ANTI-INFLAMMATORY DRUGS
- •ENZYMES AND FIBRINOLYTICS
- •MISCELLANEOUS ANTI-INFLAMMATORY AND ANTIANGIOGENIC AGENTS
- •Summary and Key points
- •ACKNOWLEDGMENTS
- •REFERENCES
- •INTRODUCTION
- •KEY CONCEPTS AND FUNDAMENTALS
- •PHARMACOLOGY, BIOCHEMISTRY, AND TYPE OF IMPACT ON THE RETINA
- •DISRUPTION OF THE RETINA AND RETINAL PIGMENT EPITHELIUM
- •Phenothiazines
- •Thioridazine
- •Chlorpromazine
- •Chloroquine derivatives
- •Chloroquine
- •Hydroxychloroquine
- •Quinine sulfate
- •Clofazimine
- •2′,3′-dideoxyinosine (DDI)
- •Deferoxamine
- •Corticosteroid preparations
- •Cisplatin and BCNU (carmustine)
- •Potassium iodate
- •VASCULAR DAMAGE OR OCCLUSION
- •Quinine sulfate
- •Cisplatin and BCNU (carmustine)
- •Talc
- •Oral contraceptives
- •Aminoglycoside antibiotics
- •Interferon
- •Miscellaneous agents
- •CYSTOID MACULAR EDEMA AND RETINAL EDEMA/FOLDS
- •CYSTOID MACULAR EDEMA
- •Epinephrine and dipivefrin
- •Nicotinic acid
- •Prostaglandin analogues
- •Retinal edema/folds
- •Sulfa antibiotics, acetazolamide, ethoxyzolamide, chlorthalidone, hydrochlorothiazide, triamterene, metronidazole
- •Topiramate
- •CRYSTALLINE RETINOPATHY
- •TAMOXIFEN
- •CANTHAXANTHINE
- •METHOXYFLURANE
- •TALC
- •NITROFURANTOIN
- •UVEITIS
- •RIFABUTIN
- •CIDOFOVIR
- •LATANOPROST
- •CARDIAC GLYCOSIDES
- •SILDENAFIL
- •METHANOL
- •VIGABATRIN
- •SUMMARY AND KEY POINTS
- •REFERENCES
- •INTRODUCTION
- •DISEASE PREVALENCE AND INFLUENCE
- •RISK FACTORS
- •ETIOLOGY/PATHOGENESIS
- •SIGNS AND SYMPTOMS
- •TREATMENT OPTIONS
- •VITAMIN C
- •CAROTENOIDS
- •VITAMIN E
- •MINERALS
- •SUMMARY AND KEY POINTS
- •REFERENCES
- •Neovascular age-related macular degeneration
- •DISEASE PREVALENCE AND INFLUENCE
- •RISK FACTORS
- •ETIOLOGY/PATHOGENESIS
- •NATURAL HISTORY
- •NONPHARMACOLOGIC THERAPIES
- •PHARMACOLOGIC THERAPIES
- •PDT WITH VERTEPORFIN
- •PEGAPTANIB
- •RANIBIZUMAB
- •BEVACIZUMAB
- •COMBINATION THERAPY
- •TREATMENTS UNDER INVESTIGATION
- •SUMMARY AND KEY POINTS
- •REFERENCES
- •Diabetic retinopathy and diabetic macular edema
- •INTRODUCTION
- •DIABETIC RETINOPATHY PREVALENCE
- •RISK FACTORS
- •ETIOLOGY AND PATHOGENESIS
- •SIGNS AND SYMPTOMS
- •TREATMENT OPTIONS
- •SUMMARY AND KEY POINTS
- •REFERENCES
- •Retinal vein occlusion
- •INTRODUCTION
- •DISEASE PREVALENCE
- •RISK FACTORS
- •PATHOGENESIS
- •CENTRAL RETINAL VEIN OCCLUSION
- •BRANCH RETINAL VEIN OCCLUSION
- •TREATMENT OPTIONS
- •CENTRAL RETINAL VEIN OCCLUSION
- •BRANCH RETINAL VEIN OCCLUSION
- •TREATMENT OUTCOMES AND PROGNOSIS
- •CENTRAL RETINAL VEIN OCCLUSION
- •TISSUE PLASMINOGEN ACTIVATOR (tPA)
- •CORTICOSTEROIDS
- •BEVACIZUMAB
- •OTHER MEDICATIONS
- •Ranimizumab
- •Coumadin (warfarin)
- •Urokinase
- •Troxerutin
- •Ticlodipine
- •Pentoxifylline
- •Hemodilution
- •Laser treatment
- •Chorioretinal venous anastomosis
- •SURGICAL TREATMENT OF CRVO
- •Radial optic neurotomy (ron)
- •Branch retinal vein occlusion
- •Corticosteroids
- •Bevacizumab
- •Ranimizumab
- •Laser treatment
- •SURGICAL TREATMENT OF BRVO
- •SUMMARY AND KEY POINTS
- •REFERENCES
- •Retinal detachment and proliferative vitreoretinopathy
- •INTRODUCTION
- •INCIDENCE OF RETINAL DETACHMENT
- •ETIOLOGY AND RISK FACTORS FOR RETINAL DETACHMENT
- •RISK FACTORS FOR PROLIFERATIVE VITREORETINOPATHY
- •SIGNS, SYMPTOMS, AND DIAGNOSIS
- •TREATMENT OPTIONS
- •PROGNOSIS WITH THE VARIOUS TREATMENT OPTIONS
- •ADJUNCTIVE THERAPIES
- •SUMMARY AND KEY POINTS
- •REFERENCES
- •Posterior Uveitis
- •INTRODUCTION
- •DISEASE PREVALENCE AND INFLUENCE
- •RISK FACTORS
- •PATHOGENESIS
- •SPECIFIC DISEASES: DIAGNOSIS AND PHARMACOTHERAPY
- •ADAMANTIADES–BEHÇET DISEASE
- •Diagnostic features
- •Treatment modalities
- •BIRDSHOT RETINOCHOROIDOPATHY
- •Diagnostic features
- •Treatment modalities
- •Treatment modalities
- •SARCOIDOSIS
- •Diagnostic features
- •Treatment modalities
- •SERPIGINOUS CHOROIDOPATHY
- •Diagnostic features
- •Treatment modalities
- •VOGT–KOYANAGI–HARADA SYNDROME
- •Diagnostic features
- •Treatment modalities
- •SYMPATHETIC OPHTHALMIA
- •Diagnostic features
- •Treatment modalities
- •SUMMARY AND KEY POINTS
- •REFERENCES
- •INTRODUCTION
- •DISEASE PREVALENCE
- •RISK FACTORS
- •MYOPIA
- •PRESUMED OCULAR HISTOPLASMOSIS SYNDROME
- •OTHER INFLAMMATORY CAUSES
- •ANGIOID STREAKS
- •IDIOPATHIC CNV
- •ETIOLOGY AND PATHOGENESIS
- •DIAGNOSIS AND ANCILLARY TESTING
- •MYOPIA
- •PRESUMED OCULAR HISTOPLASMOSIS SYNDROME
- •ANGIOID STREAKS
- •INFLAMMATORY CAUSES
- •DIFFERENTIAL DIAGNOSIS
- •CLINICAL SIGNS AND SYMPTOMS
- •MYOPIA
- •PRESUMED OCULAR HISTOPLASMOSIS SYNDROME
- •ANGIOID STREAKS
- •INFLAMMATORY CAUSES
- •TREATMENT
- •PHOTODYNAMIC THERAPY
- •SURGICAL THERAPY
- •ANTIANGIOGENIC THERAPY
- •SUMMARY AND KEY POINTS
- •REFERENCES
- •INTRODUCTION
- •DISEASE INCIDENCE
- •RISK FACTORS
- •ETIOLOGY/PATHOGENESIS
- •SIGNS AND SYMPTOMS
- •OCULAR
- •SYSTEMIC
- •TREATMENT OPTIONS
- •SUMMARY AND KEY POINTS
- •ACKNOWLEDGMENTS
- •REFERENCES
- •Retinopathy of prematurity
- •INTRODUCTION
- •DISEASE PREVALENCE AND INFLUENCE
- •RISK FACTORS
- •ETIOLOGY/PATHOGENESIS
- •ABNORMAL RETINAL VASCULARIZATION IN ROP
- •ROLE OF GROWTH FACTORS IN ROP
- •DIAGNOSIS AND ANCILLARY TESTING/DIFFERENTIAL DIAGNOSIS
- •SIGNS AND SYMPTOMS
- •CLASSIFICATION OF RETINOPATHY OF PREMATURITY
- •TREATMENT OPTIONS FOR RETINOPATHY OF PREMATURITY
- •CRYOTHERAPY AND LASER THERAPY
- •INTRAVITREAL ANTI-VEGF THERAPY FOR ROP
- •Rationale for Treatment
- •Injection Technique
- •Patients
- •Results
- •Other Reported Results
- •Concerns with Intravitreal Anti-VEGF Therapy for ROP
- •Ocular complications
- •Systemic Complications
- •Vitrectomy
- •SUMMARY
- •REFERENCES
- •Idiopathic macular telangiectasia
- •INTRODUCTION
- •THERAPY
- •NONPROLIFERATIVE STAGE
- •PROLIFERATIVE STAGE
- •SUMMARY AND KEY POINTS
- •REFERENCES
- •Neovascular glaucoma
- •INTRODUCTION
- •DISEASE PREVALENCE AND INFLUENCE
- •RISK FACTORS
- •ETIOLOGY/PATHOGENESIS
- •CENTRAL RETINAL VEIN OCCLUSION
- •DIABETIC RETINOPATHY
- •DIABETIC NEOVASCULAR GLAUCOMA
- •CAROTID ARTERY OCCLUSIVE DISEASE
- •CENTRAL RETINAL ARTERY OCCLUSION
- •INTRAOCULAR TUMORS
- •Malignant melanoma
- •Retinoblastoma
- •MISCELLANEOUS CAUSES
- •DIAGNOSIS AND ANCILLARY TESTING
- •DIFFERENTIAL DIAGNOSIS
- •SIGNS AND SYMPTOMS
- •TREATMENT OPTIONS
- •TREATMENT OF THE UNDERLYING DISEASE ASSOCIATED WITH NVG
- •Central retinal vein occlusion
- •Diabetic retinopathy
- •Carotid artery occlusive disease
- •Central retinal artery occlusion
- •PHARMACOLOGIC THERAPIES
- •Medical treatment to control high IOP
- •Anti-VEGF therapy
- •Corticosteroid therapy
- •Photodynamic therapy
- •SUMMARY AND KEY POINTS
- •REFERENCES
- •INTRODUCTION
- •SPECIFIC DISEASES
- •RETINITIS PIGMENTOSA
- •Nutrients and retinitis pigmentosa
- •Cystoid Macular Edema (CME) associated with RP
- •Ciliary Neurotrophic Factor and retinitis pigmentosa
- •REFSUM’S DISEASE
- •Treatment
- •Dietary restriction
- •Plasmapheresis
- •GYRATE ATROPHY
- •Treatment
- •Arginine-restricted diet
- •Vitamin B6 supplementation
- •ABETALIPOPROTEINEMIA (BASSEN–KORNZWEIG SYNDROME)
- •Treatment
- •LEBER CONGENITAL AMAUROSIS
- •Treatment
- •RPE65 gene therapy
- •X-LINKED JUVENILE RETINOSCHISIS
- •Treatment
- •SUMMARY AND KEY POINTS
- •REFERENCES
- •SECTION 4: Drugs and Mechanisms in Retinal Diseases
- •Nonsteroidal anti-inflammatory drugs (NSAIDs) in the treatment of retinal diseases
- •KEY FEATURES
- •INTRODUCTION AND HISTORY
- •PHARMACOLOGY, DRUG MECHANISM, AND EFFECTS
- •DICLOFENAC
- •KETOROLAC
- •NEVANAC
- •BROMFENAC
- •DICLOFENAC
- •KETOROLAC
- •NEPAFENAC
- •BROMFENAC
- •CONTRAINDICATIONS, COMPLICATIONS, AND TOXICITY
- •SUMMARY AND KEY POINTS
- •ACKNOWLEDGMENTS
- •REFERENCES
- •KEY FEATURES
- •INTRODUCTION
- •PHARMACOLOGY
- •STRUCTURE
- •METABOLISM
- •Dexamethasone
- •Fluocinolone
- •CYSTOID MACULAR EDEMA
- •DIABETIC MACULAR EDEMA
- •RETINAL VEIN OCCLUSION
- •EXUDATIVE AGE-RELATED MACULAR DEGENERATION (AMD)
- •Raised intraocular pressure
- •Infectious, sterile, and pseudoendophthalmitis associated with triamcinolone acetonide
- •Cataract
- •Retinal detachment
- •FUTURE CONSIDERATIONS AND ONGOING STUDIES
- •THE SCORE STUDY
- •STEROID-SUSTAINED RELEASE DEVICES
- •The STRIDE study
- •FLUOCINOLONE ACETONIDE DEVICE
- •NEW-GENERATION FLUOCINOLONE DEVICE
- •SUMMARY AND KEY POINTS
- •REFERENCES
- •Anecortave acetate
- •KEY FEATURES
- •INTRODUCTION AND HISTORY
- •PHARMACOLOGY
- •DRUG MECHANISM
- •DRUG EFFECTS IN RETINAL DISEASES
- •PRECLINICAL STUDIES
- •Retinopathy of prematurity
- •Intraocular tumors
- •Choroidal neovascularization
- •CLINICAL STUDIES
- •Exudative AMD
- •Other diseases
- •EFFICACY AND COMPARISON WITH OTHER AGENTS
- •CONTRAINDICATIONS
- •OCULAR COMPLICATIONS AND TOXICITY
- •SYSTEMIC COMPLICATIONS AND TOXICITY
- •DRUG INTERACTIONS
- •SUMMARY AND KEY POINTS
- •ACKNOWLEDGMENTS
- •REFERENCES
- •KEY FEATURES
- •INTRODUCTION AND HISTORY
- •PHARMACOLOGY
- •DRUG MECHANISM
- •DRUG USE IN RETINAL DISEASES
- •AGE-RELATED MACULAR DEGENERATION
- •DIABETIC RETINOPATHY
- •RETINAL VEIN OCCLUSION (RVO)
- •UVEITIC CYSTOID MACULAR EDEMA (CME)
- •RETINOPATHY OF PREMATURITY (ROP)
- •RETINAL TELANGIECTASIAS
- •NEOVASCULAR GLAUCOMA (NVG)
- •OTHERS
- •CONTRAINDICATIONS
- •OCULAR COMPLICATIONS AND TOXICITY
- •SYSTEMIC COMPLICATION AND TOXICITY
- •DRUG INTERACTIONS
- •SUMMARY AND KEY POINTS
- •REFERENCES
- •KEY FEATURES
- •INTRODUCTION AND HISTORY
- •PHARMACOLOGY
- •PHARMACOLOGICAL DESIGN
- •PHARMACOKINETICS
- •PHARMACODYNAMICS
- •DRUG MECHANISM
- •DRUG USE IN RETINAL DISEASES
- •EFFICACY
- •EFFICACY IN AMD
- •EFFICACY IN OTHER RETINAL DISEASES
- •CONTRAINDICATIONS
- •OCULAR COMPLICATIONS AND TOXICITY
- •DRUG INTERACTIONS
- •SUMMARY AND KEY POINTS
- •REFERENCES
- •Pathophysiology of vascular endothelial growth factor and other angiogenic molecules
- •KEY FEATURES
- •INTRODUCTION
- •BIOLOGICAL EFFECTS OF VEGF-A
- •VEGF-A ISOFORMS
- •VEGF RECEPTORS
- •ROLE OF VEGF-A IN INTRAOCULAR NEOVASCULAR SYNDROMES
- •INTRAVITREAL ANTI-VEGF THERAPY FOR NEOVASCULAR AMD: PEGAPTANIB, RANIBIZUMAB AND BEVACIZUMAB
- •OTHER ANTI-VEGF THERAPIES IN CLINICAL DEVELOPMENT FOR AMD
- •OTHER ANGIOGENIC FACTORS
- •FIBROBLAST GROWTH FACTOR FAMILY
- •PLACENTAL GROWTH FACTOR
- •DELTA-LIKE LIGAND 4
- •SUMMARY AND KEYPOINTS
- •REFERENCES
- •KEY FEATURES
- •INTRODUCTION
- •TUMOR NECROSIS FACTOR-ALPHA ANTAGONISTS
- •INFLIXIMAB (REMICADE)
- •Pharmacology and mechanism
- •Systemic indications for infliximab
- •Ophthalmic indications for infliximab
- •Contraindications
- •Ocular complications and toxicity
- •Systemic complications and toxicity
- •Drug interactions
- •Summary
- •ADALIMUMAB (HUMIRA)
- •Pharmacology and mechanism
- •Systemic indications
- •Ophthalmic indications
- •Contraindications
- •Ocular toxicity
- •Systemic toxicity
- •Drug interactions
- •Summary
- •ETANERCEPT (ENBREL)
- •Pharmacology and mechanism
- •Systemic indications
- •Ophthalmic indications
- •Contraindications
- •Ocular toxicity
- •Systemic toxicity
- •Drug interactions
- •Summary
- •INTERLEUKIN-2 RECEPTOR ANTAGONIST
- •DACLIZUMAB (ZENAPAX)
- •Pharmacology and mechanism
- •Systemic indication
- •Ophthalmic indications
- •Contraindications
- •Ocular toxicity
- •Systemic toxicity
- •Drug interactions
- •Summary
- •OTHER BIOLOGIC AGENTS
- •SUMMARY AND KEY POINTS
- •REFERENCES
- •KEY FEATURES
- •CALCINEURIN INHIBITORS
- •CICLOSPORIN (CYCLOSPORIN: CsA)
- •Key features, introduction, and history
- •Pharmacology
- •Drug effects in human nonocular diseases
- •Drug use in retinal diseases
- •Pediatric case series
- •EFFICACY AND COMPARISON WITH OTHER AGENTS
- •Ciclosporin versus tacrolimus
- •TACROLIMUS
- •Key features, introduction, and history
- •Pharmacology
- •Drug effects in human nonocular diseases
- •Drug use in retinal diseases
- •Summary and key points
- •ANTIMETABOLITES
- •MYCOPHENOLATE MOFETIL (MMF)
- •Key features, introduction, and history
- •Pharmacology
- •Drug mechanism
- •Drug effects in human nonocular diseases
- •Drug use in retinal diseases
- •Pediatric case series
- •METHOTREXATE
- •Key features, introduction, and history
- •Pharmacology
- •Drug mechanism
- •Drug effects in human nonocular diseases
- •Drug use in retinal diseases
- •Pediatric case series
- •Intravitreal methotrexate injection
- •AZATHIOPRINE
- •Key features, introduction, and history
- •Pharmacology
- •Drug mechanism
- •Drug effects in human nonocular diseases
- •Drug use in retinal diseases
- •Pediatric case series
- •Summary and key points
- •ALKYLATING AGENTS
- •CYCLOPHOSPHAMIDE
- •Key features, introduction, and history
- •Pharmacology
- •Drug effects in human nonocular diseases
- •Drug use in retinal diseases
- •Efficacy and comparison with other agents
- •CHLORAMBUCIL
- •Key features, introduction, and history
- •Pharmacology
- •Drug effects in human nonocular diseases
- •Drug use in retinal diseases
- •Efficacy and comparison with other agents
- •Summary and key points
- •SUMMARY
- •REFERENCES
- •KEY FEATURES
- •INTRODUCTION AND HISTORY
- •PHARMACOLOGY
- •DRUG MECHANISM
- •DRUG EFFECTS IN PRECLINICAL MODELS
- •SYSTEMIC AND OCULAR COMPLICATIONS AND TOXICITY
- •BIOACTIVITY IN HUMAN EYE DISEASES
- •NEOVASCULAR AMD PHASE I
- •NEOVASCULAR AMD PHASE III PROGRAM
- •SUMMARY AND KEY POINTS
- •REFERENCES
- •KEY FEATURES
- •INTRODUCTION AND HISTORY
- •PHARMACOLOGY
- •PHARMACOKINETICS
- •DRUG MECHANISM
- •DRUG USE IN RETINAL DISEASES
- •DIABETIC RETINOPATHY
- •RETINAL VEIN OCCLUSION
- •OTHERS
- •CONTRAINDICATIONS
- •OCULAR COMPLICATIONS AND TOXICITY
- •DRUG INTERACTIONS
- •SUMMARY AND KEY POINTS
- •REFERENCES
- •KEY FEATURES
- •INTRODUCTION TO PROTEIN KINASE C
- •PROTEIN KINASE C FAMILY
- •EFFECTS OF ACTIVATED PKC
- •PHARMACOLOGY OF RUBOXISTAURIN
- •EFFECT OF RUBOXISTAURIN IN HUMAN NONOCULAR DISEASES
- •Use of PKC Inhibitors in the treatment of diabetic macular edema and diabetic retinopathy
- •EFFICACY OF RUBOXISTAURIN IN THE TREATMENT OF DIABETIC RETINOPATHY
- •OCULAR AND SYSTEMIC COMPLICATIONS AND TOXICITY OF RUBOXISTAURIN
- •INTERACTION OF RUBOXISTAURIN WITH OTHER DRUGS
- •SUMMARY AND KEY POINTS
- •REFERENCES
- •KEY FEATURES
- •INTRODUCTION AND HISTORY OF SIRNA FOR RETINAL DISEASES
- •PHARMACOLOGY, DRUG MECHANISM, AND DRUG EFFECTS IN NONOCULAR DISEASES
- •DRUG USES IN RETINAL DISEASES
- •BEVASIRANIB FOR SUBFOVEAL CHOROIDAL NEOVASCULARIZATION
- •BEVASIRANIB FOR NEOVASCULAR MACULAR DEGENERATION: RESULTS
- •BEVASIRANIB FOR THE TREATMENT OF DIABETIC MACULAR EDEMA (DME)
- •SIRNA-027 FOR SUBFOVEAL CHOROIDAL NEOVASCULARIZATION
- •REDD14 NP
- •SUMMARY AND KEY POINTS
- •ACKNOWLEDGMENT
- •REFERENCES
- •Ocular gene therapy
- •KEY FEATURES
- •INTRODUCTION TO GENE THERAPY
- •CURRENT VIRAL VECTORS
- •VIRAL VECTOR-ASSOCIATED RISKS
- •VIRAL VERSUS NONVIRAL VECTORS
- •STRATEGIES FOR RECESSIVE VERSUS DOMINANT DISEASE
- •STRATEGIES FOR PROLIFERATIVE AND NEOPLASTIC OCULAR DISEASE
- •RETINOBLASTOMA GENE THERAPY CLINICAL TRIAL
- •GENE THERAPY FOR LEBER’S CONGENITAL AMAUROSIS TRIAL
- •SUMMARY AND KEYPOINTS: THE FUTURE OF GENE THERAPY
- •REFERENCES
- •KEY FEATURES
- •INTRODUCTION
- •MECHANISM OF PROTECTION: APPROACHES AND CHALLENGES
- •ANTIOXIDATIVE THERAPY
- •EXCITOTOXICITY
- •NEUROTROPHIC FACTORS
- •ANTIAPOPTOPIC THERAPY
- •SUMMARY AND KEY POINTS
- •REFERENCES
- •KEY FEATURES
- •INTRODUCTION AND HISTORY
- •PHARMACOLOGY
- •DRUG MECHANISM
- •PDT IN ONCOLOGICAL DISORDERS
- •PDT IN IMMUNE (NONONCOLOGICAL) DISORDERS
- •DRUG USE IN RETINAL DISEASES
- •AGE-RELATED MACULAR DEGENERATION
- •PATHOLOGIC MYOPIA
- •OTHER SUBFOVEAL AND JUXTAFOVEAL POSTINFLAMMATORY OR IDIOPATHIC CHOROIDAL NEOVASCULARIZATION
- •POLYPOIDAL CHOROIDAL VASCULOPATHY
- •CENTRAL SEROUS CHORIORETINOPATHY
- •INTRAOCULAR VASOPROLIFERATIVE TUMORS
- •RETINAL ASTROCYTOMA
- •CHOROIDAL OSTEOMA
- •CHOROIDAL MELANOMA
- •RETINOBLASTOMA
- •CONJUNCTIVAL IN SITU SQUAMOUS CELL CARCINOMA
- •EFFICACY AND COMPARISON WITH OTHER AGENTS
- •CONTRAINDICATIONS
- •OCULAR COMPLICATIONS AND TOXICITY
- •DRUG INTERACTIONS
- •SUMMARY AND KEY POINTS
- •REFERENCES
- •KEY FEATURES
- •INTRODUCTION
- •RETINOBLASTOMA (Tables 44.1 and 44.2)
- •GENERAL CONSIDERATIONS
- •CHEMOREDUCTION
- •AGENTS
- •RESULTS
- •CHEMOREDUCTION FAILURE
- •SIDE-EFFECTS
- •CHEMOTHERMOTHERAPY
- •PERIOCULAR AND SUBCONJUNCTIVAL CHEMOTHERAPY
- •INTRAVITREAL CHEMOTHERAPY
- •INTRA-ARTERIAL CHEMOTHERAPY
- •ADJUVANT CHEMOTHERAPY
- •NO CHOROIDAL, SCLERAL, OR POSTLAMINAR OPTIC NERVE INVOLVEMENT
- •CHOROIDAL INVASION
- •POSTLAMINAR OPTIC NERVE INVASION
- •TUMOR AT CUT OPTIC NERVE MARGIN
- •METASTATIC RETINOBLASTOMA
- •UVEAL METASTASIS
- •GENERAL CONSIDERATIONS
- •CHEMOTHERAPY
- •PROGNOSIS
- •UVEAL MELANOMA
- •METASTATIC UVEAL MELANOMA
- •INTRAOCULAR LYMPHOMA
- •GENERAL CONSIDERATIONS
- •TREATMENT
- •SUMMARY AND KEYPOINTS
- •REFERENCES
- •Antibiotics
- •INTRODUCTION
- •POTENTIAL NEW TREATMENT REGIMENS
- •TOPICAL FLUOROQUINOLONES
- •ORAL AND INTRAVENOUS ANTIBIOTICS
- •NASALLY APPLIED ANTIBIOTICS
- •ORAL, TOPICAL, AND INTRAVITREAL ANTIFUNGAL AGENTS
- •CONCLUSION
- •REFERENCES
- •SECTION 5: Pharmacotherapy and Surgery
- •KEY FEATURES (PHARMACOLOGY)
- •INTRODUCTION AND HISTORY
- •RHEOPHERESIS IN RETINAL DISEASES
- •AGE-RELATED MACULAR DEGENERATION
- •MAC-1 trial
- •Multicenter investigation of rheopheresis for AMD (MIRA-1)
- •DIABETIC MACULOPATHY
- •CENTRAL RETINAL VEIN OCCLUSION
- •UVEAL EFFUSION SYNDROME
- •Complications
- •SUMMARY
- •REFERENCES
- •Enzymatic vitrectomy and pharmacologic vitreodynamics
- •INTRODUCTION AND HISTORY
- •PHARMACOLOGY AND BIOCHEMISTRY
- •INDICATIONS
- •SURGICAL ADJUNCT
- •NONSURGICAL INDICATIONS
- •OPERATIVE TECHNIQUES
- •OUTCOMES
- •SUMMARY
- •REFERENCES
- •KEY FEATURES, INTRODUCTION, AND HISTORY
- •RATIONALE
- •PHARMACOLOGY AND BIOCHEMISTRY
- •INDICATIONS, OUTCOMES, AND COMPLICATIONS – VITAL DYES IN CHROMOVITRECTOMY
- •INDOCYANINE GREEN
- •INFRACYANINE GREEN
- •TRYPAN BLUE
- •PATENT BLUE
- •BRILLIANT BLUE
- •SODIUM FLUORESCEIN (SF)
- •TRIAMCINOLONE ACETONIDE
- •DYE INJECTION
- •MACULAR HOLE PROTECTION
- •SUMMARY AND KEY POINTS
- •REFERENCES
- •KEY FEATURES
- •INTRODUCTION AND HISTORY
- •BIOLOGICAL EFFECTS
- •INDICATIONS
- •CHOROIDAL MELANOMA
- •OTHER OCULAR TUMORS
- •OPERATIVE TECHNIQUES
- •PLAQUE PLACEMENT TECHNIQUE
- •EPIMACULAR BRACHYTHERAPY FOR AGE-RELATED MACULAR DEGENERATION
- •SURGICAL TECHNIQUE
- •OUTCOMES
- •CHOROIDAL MELANOMA
- •BRACHYTHERAPY FOR AGE-RELATED MACULAR DEGENERATION
- •COMPLICATIONS
- •RADIATION RETINOPATHY
- •OPTIC NEUROPATHY
- •LENS TOXICITY
- •SCLERA/CHOROID TOXICITY
- •SUMMARY AND KEY POINTS
- •REFERENCES
- •INTRODUCTION
- •RPE DISEASE AND INDICATIONS FOR TREATMENT BY TRANSPLANTATION
- •BRUCH’S MEMBRANE AS A SUBSTRATE FOR TRANSPLANTED RPE
- •HISTORICAL DEVELOPMENT OF RPE TREATMENT
- •AUTOLOGOUS TREATMENT
- •IRIS PIGMENT EPITHELIUM
- •RETINAL PIGMENT EPITHELIUM
- •Suspension
- •RPE-BM Choroid Sheet
- •TISSUE ENGINEERING AND RPE REPLACEMENT STRATEGIES
- •PROSTHESIS OR TISSUE ENGINEERING OF BRUCH’S MEMBRANE
- •STEM CELLS
- •Embryonic stem cells
- •Bone marrow-derived cells
- •MANAGING DECONSTRUCTIVE REACTIONS INDUCED BY RETINAL DETACHMENT
- •CONCLUSIONS AND FUTURE DIRECTIONS
- •ACKNOWLEDGMENTS
- •REFERENCES
- •SECTION 6: The Last Words
- •Off-label drugs and the impact of the Food and Drug Administration in the treatment of retinal disease
- •INTRODUCTION
- •OFF-LABEL DRUG USAGE AND THE FOOD AND DRUG ADMINISTRATION
- •HISTORICAL PERSPECTIVES
- •FDA APPROVAL PROCESS
- •THE CONCEPT OF “OFF-LABEL”
- •“INVESTIGATIONAL USAGE OF DRUGS”
- •COMPOUNDING PHARMACIES
- •RISK MANAGEMENT ISSUES
- •INFORMED CONSENT
- •MEDICAL PAYMENT/COVERAGE
- •NATIONAL COVERAGE DETERMINATION
- •CLINICAL TRIALS
- •SUMMARY AND KEY POINTS
- •REFERENCES
- •INTRODUCTION
- •HISTORY
- •KEY CONCEPTS
- •EVIDENCE-BASED MEDICINE
- •TYPES OF PHARMACOECONOMIC ANALYSIS
- •COST MINIMIZATION ANALYSIS
- •COST–BENEFIT ANALYSIS
- •COST-EFFECTIVENESS ANALYSIS
- •Cost-effectiveness analysis
- •COST–UTILITY ANALYSIS
- •Quality of life: Function-based instruments
- •Quality of life: Preference-based instruments
- •Utility gain
- •Value gain
- •Value trumps cost
- •Cost–utility ratio
- •Cost-effectiveness standards
- •Discounting5
- •Value-based medicine
- •Standardization
- •Patient respondents
- •COST PERSPECTIVE
- •SUMMARY AND KEY POINTS
- •REFERENCES
- •Future perspectives:
- •INTRODUCTION
- •KEY FEATURES
- •ANGIOGENESIS AND NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
- •TYROSINE KINASE INHIBITORS
- •PDGF INHIBITORS
- •INTEGRIN INHIBITORS
- •SMALL INTERFERING RNA
- •BIOACTIVE LIPIDS
- •NONNEOVASCULAR AGE-RELATED MACULAR DEGENERATION
- •COMPLEMENT INHIBITORS
- •DIABETIC MACULAR EDEMA
- •INHIBITION OF INFLAMMATION
- •SUMMARY AND KEY POINTS
- •ACKNOWLEDGMENT
- •REFERENCES
- •Index
CHOROIDAL MELANOMA
PDT with verteporfin has shown promising results in animal studies of choroidal melanoma. However, few patients worldwide have undergone this treatment. In the management of lesions that have failed to respond to brachytherapy and transpupillary thermotherapy, PDT may prevent eyes from undergoing enucleation.30
The potential advantage of PDT for lesions close to the macula is a greater potential for preservation of visual acuity. The major disadvantage is the potential for external recurrence despite a normal internal retinal appearance, a complication well described with transpupillary thermotherapy. The role of PDT in this condition, either as primary treatment or as an adjuvant treatment with plaque brachytherapy, remains experimental.
RETINOBLASTOMA
PDT using verteporfin efficiently kills chemotherapy-resistant and nonresistant retinoblastoma cell lines and primary tumor cells in vitro, and it warrants further preclinical evaluation as a therapeutic option for the treatment of retinoblastoma.31
CONJUNCTIVAL IN SITU SQUAMOUS CELL CARCINOMA
There is histopathological evidence that PDT with verteporfin is effective in treating at least in situ squamous cell carcinoma. Further studies are required to investigate this proposed modality in order to assess whether cure rates, recurrence rates, and cost-effectiveness are comparable with other treatment modalities.32
PDT has also been effective in recurrent hyphema caused by abnormal intralesional blood vessels after proton beam irradiation of iris melanoma.
EFFICACY AND COMPARISON WITH OTHER AGENTS
Visual outcomes after PDT with verteporfin and other treatment modalities in patients with AMD are shown in Tables 43.1 and 43.2. In terms of general efficacy, PDT with verteporfin is able to prevent further severe visual loss. In AMD, the risk of a significant loss in vision is reduced to 50% compared to the spontaneous course of the disease.13
The recent development of anti-VEGF substances for use in clinical routine has markedly improved the prognosis of patients with neovascular AMD. Intravitreal treatment with substances targeting all isotypes of VEGF provide vision maintenance in over 90% and substantial improvement in 25–40% of patients with AMD.35,36 However, PDT using verteporfin seems to be the most promising treatment for polypoidal choroidal vasculopathy.23
Verteporfin may still play an important role in the management of these patients, as the combination with occlusive therapies like PDT with verteporfin may offer a reduction of retreatment frequency and long-term maintenance of the treatment benefit.16
CONTRAINDICATIONS
PDT with verteporfin is contraindicated for patients with porphyria or a known hypersensitivity to any component of this preparation.
CORNEAL AND IRIS
NEOVASCULARIZATION
PDT with verteporfin may be effective for the treatment of corneal neovascularization secondary to different ocular conditions.33
PDT with verteporfin can partially obliterate anterior-segment neovascularizations secondary to ischemic central retinal vein occlusion, preventing the evolution towards advanced stages of neovascular glaucoma, but is not effective in cases with complete angle synechial closure.34
OCULAR COMPLICATIONS AND TOXICITY
Verteporfin therapy is a particularly safe treatment in terms of ocular safety. In AMD patients, serious adverse events, including acute severe vision loss, arteriolar or venular nonperfusion, retinal capillary nonperfusion, or vitreous hemorrhage, occurred in 3.8% of verteporfin-treated patients and 1.4% of placebo recipients. Severe vision loss (defined as a decrease of at least 4 lines of visual acuity occurring within 7 days of treatment) occurs rarely and is more often seen in the treatment of large occult lesions with a high initial BCVA.37
Table 43.2 Improvement of ≥ 3 lines with different treatments in age-related macular degeneration
Treatment modality |
Lesion type |
Study |
Control |
Difference |
Study |
PDT |
Predominantly + minimum classic CNV |
9% |
4% |
5% |
TAP: 24 months |
|
Occult CNV |
5% |
1% |
4% |
VIP: 24 months |
Pegabtanib 0.3 mg |
All CNV subtypes |
6% |
2% |
4% |
VISION: 24 months |
Ranibizumab 0.5 mg |
Predominantly. classic CNV |
41% |
6% |
35% |
ANCHOR: 24 months |
|
Minimum classic + occult CNV |
33% |
4% |
29% |
MARINA: 24 months |
Ranibizumab 0.5 mg (3-monthly) |
All CNV types |
13% |
10% |
3% |
PIER: 12 months |
Combination PDT–ranibizumab |
Predominantly classic CNV |
24% |
5% |
19% |
FOCUS: 12 months |
|
|
|
|
|
|
PDT, photodynamic therapy; CNV, choroidal neovascularization; TAP, treatment of age-related macular degeneration with photodynamic therapy; VIP, Verteporfin in Photodynamic Therapy study; VISION, VEGF Inhibition Study in Ocular Neovascularization; ANCHOR, Anti-VEGF antibody for the treatment of predominantly classic choroidal neovascularization in age-related macular degeneration; MARINA, Minimally classic/occult trial of the anti-VEGF antibody ranibizumab in the treatment of neovascular age-related macular degeneration; PIER, A phase IIIB multicenter, randomized, double-masked, sham injection controlled study of the efficacy and safety of ranibizumab in subjects with subfoveal CNV with or without classic CNV secondary to age-related macular degeneration; FOCUS, A phase I/II, single-masked multicenter study of the safety, tolerability, and efficacy of multiple-dose intravitreal injections of rhuFab V2 I combination with verteporfin (Visudyne) photodynamic therapy in subjects with neovascular age-related macular degeneration.
Diseases Retinal in Mechanisms and Drugs • 4 section
303
Verteporfin Therapy: Photodynamic• 43 chapterand Photosensitizers
In lesions with serous detachment of the RPE, mechanical rips were observed. Expanding pigment epithelial detachments (PEDs) and those with nonhomogeneous filling may represent high-risk lesions because they may eventually exert sufficient tangential stress to result in a spontaneous tear.38 In retinal angiomatous proliferation, RPE tears are more common when the PED exceeds 50% of the lesion. Visual recovery after RPE tear is uncommon but possible in some instances, especially when the fovea is spared and conserves the RPE.
No cases of retinal arteriole or venular nonperfusion were reported at the 50 J/cm2 light dose used in the clinical studies or in clinical practice. However, in the phase I/II dose-finding study, retinal arteriole and venular nonperfusion were seen at a higher light dose of 150 J/cm2. These data suggest that, to provide safe and effective treatment, the recommended light dose of 50 J/cm2 should not be exceeded.
The most frequently reported ocular adverse events were transient visual disturbances, which were reported at an incidence of 12.4–29.8% in verteporfin-treated patients and 6.8–12.8% in placebo patients.
No clinically significant ocular adverse events occurred in either treatment group in patients with pathologic myopia or OHS.20,21
SYSTEMIC COMPLICATIONS
AND TOXICITY
Verteporfin therapy is a particularly safe treatment in terms of systemic safety.
The most frequently reported nonocular adverse events to PDT with verteporfin are injection site reactions (including pain, edema, inflammation, extravasation, rashes, hemorrhage, and discoloration).37
Table 43.3 show the ocular and nonocular adverse events, listed by body system, that were reported more frequently with verteporfin therapy than with placebo therapy and occurred in 1–10% of patients.
Photosensitivity reactions were reported in 2.2% of patients. Compliance with photosensitivity protection instructions will minimize the potential for photosensitivity reactions.
Table 43.3 Adverse events, listed by body system, that were reported more frequently with verteporfin therapy than with placebo therapy and occurred in 1–10% of patients
Ocular treatment site |
|
Blepharitis, cataracts, conjunctivitis/ |
|
||
|
|
conjunctival injection, dry eyes, ocular |
|
|
itching, severe vision decrease with or |
|
|
without subretinal/retinal or vitreous |
|
|
hemorrhage |
Body as a whole |
|
Asthenia, fever, flu syndrome, infusion- |
|
|
related pain primarily presenting as |
|
|
back pain, photosensitivity reactions |
Cardiovascular |
|
Atrial fibrillation, hypertension, |
|
|
peripheral vascular disorder, varicose |
|
|
veins |
Dermatologic |
|
Eczema |
Digestive |
|
Constipation, gastrointestinal cancers, |
|
|
nausea |
Hematic and lymphatic |
|
Anemia, decreased white blood cell |
|
|
count, increased white blood cell count |
Hepatic |
|
Elevated liver function tests |
Metabolic/nutritional |
|
Albuminuria, creatinine increased |
Musculoskeletal |
|
Arthralgia, arthrosis, myasthenia |
Nervous system |
|
Hypesthesia, sleep disorder, vertigo |
Respiratory |
|
Cough, pharyngitis, pneumonia |
Special senses |
|
Cataracts, decreased hearing, diplopia, |
|
|
lacrimation disorder |
Urogenital |
|
Prostatic disorder |
|
|
|
PDT with verteporfin does not appear to cause teratogenicity, mutagenicity, hepatotoxicity, or significant cardiovascular toxicity.39
However, PDT has been reported to result in DNA damage. No studies have been conducted to evaluate the carcinogenic potential of verteporfin. It is not known how the potential for DNA damage with PDT agents translates into human risk. No effect on male or female fertility has been observed in rats following intravenous administration of verteporfin for injection up to 10 mg/kg/day.
PDT with verteporfin has a pregnancy category of C. Studies in animals have revealed adverse effects on fetus but there are no controlled studies in women. Thus, verteporfin should be given only if the potential benefit justifies the potential risk to the fetus.
Verteporfin and its diacid metabolite have been found in the breast milk of one woman after a 6 mg/m2 infusion. Because of the potential for serious adverse reactions in nursing infants from verteporfin, a decision should be made whether to discontinue nursing or postpone treatment, taking into account the importance of the drug to the mother.
Safety and effectiveness in pediatric patients have not been established.
Multiple-dose studies in rats and dogs given intravenous verteporfin with and without light application showed treatment-related hematopoietic effects in the bone marrow, liver, and spleen only at doses at least 66 times higher than the single 6 mg/m2 body surface area (approximately 0.15 mg/kg) dose of Visudyne used clinically at 3-month intervals.39
DRUG INTERACTIONS
Drug interaction studies in humans have not been conducted with PDT with verteporfin.
Verteporfin is rapidly eliminated by the liver, mainly as unchanged drug. Metabolism is limited and occurs by liver and plasma esterases. Microsomal cytochrome P450 does not appear to play a role in verteporfin metabolism. Thus, clinically significant drug–drug interactions are unlikely, as NADPH-dependent enzymes, such as cytochrome P450 isozymes, do not play a significant role in verteporfin metabolism.4
Based on the mechanism of action of verteporfin, many drugs used concomitantly could influence the effect of PDT with verteporfin. Calcium channel blockers, polymyxin B, or radiation therapy could enhance the rate of verteporfin uptake by the vascular endothelium. On the contrary, compounds that quench active oxygen species or scavenge radicals (e.g., dimethyl sulfoxide, β-carotene, ethanol, formate, and mannitol), and drugs that decrease clotting, vasoconstriction or platelet aggregation (e.g., thromboxane A2 inhibitors), may decrease PDT with verteporfin activity.
However, no obvious drug–drug interactions were seen in the pivotal placebo-controlled studies of PDT with verteporfin, in which 95% of the population received concomitant medications. including some of the above classes of agents.
It is possible that other photosensitizing agents (e.g., tetracyclines, sulfonamides, phenothiazines, sulfonylurea hypoglycemic agents, thiazide diuretics, and griseofulvin) could increase the potential for skin photosensitivity reactions.
SUMMARY AND KEY POINTS
Veteporfin is a second-generation photosensitizer, displaying rapid clearance and consequently a reduced period of skin photosensitivity compared with the first-generation photosensitizer, porfimer sodium.
PDT with verteporfin is a disease site-specific treatment modality that is particularly safe in terms of both systemic and ocular safety. It involves the local or systemic administration of a lipophilic photosensitizing drug that selectively accumulates within rapidly dividing cells, such as neovascular endothelial cells, tumor cells, as well as activated cells of the immune system, followed by irradiating the targeted disease site with nonthermal visible light of appropriate wavelength. In the
304
presence of molecular oxygen, the activation of the photosensitizer and energy transfer can lead to a series of photochemical reactions and generation of various cytotoxic species (e.g., singlet oxygen and other reactive oxygen species), and consequently induce apoptosis and necrosis of targeted cells and tissues.
PDT with verteporfin is an established treatment for oncological disorders and nononcological disorders, such as AMD and immunemediated conditions.
In ophthalmology, PDT with verteporfin is FDA-approved for the treatment of patients with predominantly classic subfoveal CNV due to AMD, pathologic myopia, or presumed ocular histoplasmosis.
Verteporfin therapy is a particularly safe treatment in terms of both systemic and ocular safety. In terms of general efficacy, the treatment is able to prevent further severe visual loss in patients with neovascular AMD with predominantly classic CNV.11–14
In patients with polypoidal choroidal vasculopathy, PDT with verteporfin seems to be the most promising treatment.23 Further studies are needed to determine the efficacy of other treatments.
The recent development of anti-VEGF substances for use in clinical routine has markedly improved the prognosis of patients with neovascular AMD. Intravitreal treatment with substances targeting all isotypes of VEGF provide vision maintenance in over 90% and substantial improvement in 25–40% of patients.35,36
However, verteporfin may still play an important role in the management of these patients, as the combination with occlusive therapies like PDT with verteporfin may offer a reduction of retreatment frequency and long-term maintenance of the treatment benefit.
REFERENCES
1.Aveline B, Hasan T, Redmond RW. Photophysical and photosensitizing properties of benzoporphyrin derivative monoacid ring A (BPD-MA). Photochem Photobiol 1994;59:328–335.
2.Schmidt-Erfurth U, Hasan T. Mechanisms of action of photodynamic therapy with verteporfin for the treatment of age-related macular degeneration. Surv Ophthalmol 2000;45:195–214.
3.Li JH, Chen YP, Zhao SD, et al. Application of hematoporphyrin derivative and laser-induced photodynamical reaction in the treatment of lung cancer: a preliminary report on 21 cases. Lasers Surg Med 1984;4(1):31–37.
4.Houle JM, Strong A. Clinical pharmacokinetics of verteporfin. J Clin Pharmacol 2002 May;42(5):547–557.
5.Allison BA, Pritchard PH, Levy JG. Evidence for low-density lipoprotein receptor-mediated uptake of benzoporphyrin derivative. Br J Cancer 1994;69:833–839.
6.Chen WR, Singhal AK, Liu H, et al. Antitumor immunity induced by laser immunotherapy and its adoptive transfer. Cancer Res 2001;61:459–461.
7.Rousset N, Vonarx V, Eléouet S, et al. Effects of photodynamic therapy on adhesion molecules and metastasis. J Photochem Photobiol B 1999;52(1–3):65–73.
8.Pervaiz S, Olivo M. Art and science of photodynamic therapy. Clin Exp Pharmacol Physiol 2006;33:551–556.
9.Bissonnette R, McLean DI, Reid G, et al. Photodynamic therapy of psoriasis and psoriatic arthritis with BPD verteporfin. 7th Biennial Congress of the International Photodynamic Association; 1998 Jul 7–9; Nantes France, RC87: abstract no. 87.
10.Hendrich C, Huttmann G, Vispo-Seara JL, et al. Experimental photodynamic laser therapy for rheumatoid arthritis with a second generation photosensitizer. Knee Surg Sports Traumatol Arthrosc 2000;8(3):190–194.
11.Kaiser PK. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: 5-year results of two randomized clinical trials with an open-label extension: TAP report no. 8. Graefes Arch Clin Exp Ophthalmol 2006 Sep;244(9):1132–1142.
12.Bressler NM. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials. TAP report 2. Arch Ophthalmol 2001;119:198–207.
13.Pieramici DJ, Bressler SB, Koester JM, et al. Occult with no classic subfoveal choroidal neovascular lesions in age-related macular degeneration: clinically relevant natural history information in larger lesions with good vision from the Verteporfin in Photodynamic Therapy (VIP) trial: VIP report no. 4. Arch Ophthalmol 2006;124:660–664.
14.VIP Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization. Am J Ophthalmol 2001;131:541–560.
15.Kaiser PK. Visudyne In Occult CNV (VIO) study group. Verteporfin PDT for subfoveal occult CNV in AMD: two-year results of a randomized trial. Curr Med Res Opin 2009 Aug;25(8):1853–1860.
16.Schmidt-Erfurth U, Schlötzer-Schrehard U, Cursiefen C, Michels S, Beckendorf A, Naumann GO. Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epithelium-derived factor. Invest Ophthalmol Vis Sci 2003 Oct;44(10):4473–4480.
17.Maberley D, Canadian Retinal Trials Group. Photodynamic Therapy and Intravitreal Triamcinolone for Neovascular Age-Related Macular Degeneration A Randomized Clinical Trial. Ophthalmology 2009 Sep 11. [Epub ahead of print]
18.Schmidt-Erfurth UM, Richard G, Augustin A, et al. Guidance for the treatment of neovascular age-related macular degeneration. Acta Ophthalmol Scand 2007 Aug;85(5):486–494.
19.Frank Holz. Preliminary results of the MONTBLANC study. The 2009 International AMD and Retina Congress. Athens, Greece. October 2009.
20.Verteporfin in Photodynamic Therapy Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. 1-year results of a randomized clinical trial-VIP report no. 1. Ophthalmology 2001;108:841–852.
21.Saperstein DA, Rosenfeld PJ, Bressler NM, et al. Verteporfin therapy for CNV secondary to OHS. Ophthalmology 2006 Dec;113(12):2371.e1– 2371.e3.
22.Ruiz-Moreno JM, Montero JA, Arias L, et al. Photodynamic therapy in subfoveal and juxtafoveal idiopathic and postinflammatory choroidal neovascularization. Acta Ophthalmol Scand 2006 Dec;84(6):743–748.
23.Gomi F, Tano Y. Polypoidal choroidal vasculopathy and treatments. Curr Opin Ophthalmol 2008 May;19(3):208–212.
24.Chan WM, Lai TY, Lai RY, et al. Half-dose verteporfin photodynamic therapy for acute central serous chorioretinopathy: one-year results of a randomized controlled trial. Ophthalmology 2008 Oct;115(10):1756–1765.
25.Michels S, Michels R, Simader C, et al. Verteporfin therapy for choroidal hemangioma: a long-term follow-up. Retina 2005 Sep;25(6):697–703.
26.Blasi MA, Scupola A, Tiberti AC, et al. Photodynamic therapy for vasoproliferative retinal tumors. Retina 2006 Apr;26(4):404–409.
27.Ziemssen F, Voelker M, Inhoffen W, et al. Combined treatment of a juxtapapillary retinal capillary haemangioma with intravitreal bevacizumab and photodynamic therapy. Eye 2007 Aug;21(8):1125–1126.
28.Eskelin S, Tommila P, Palosaari T, Kivelä T. Photodynamic therapy with verteporfin to induce regression of aggressive retinal astrocytomas. Acta Ophthalmol 2008 Nov;86(7):794–799.
29.Shields CL, Materin MA, Mehta S, et al. Regression of extrafoveal choroidal osteoma following photodynamic therapy. Arch Ophthalmol 2008 Jan;126(1):135–137.
30.Barbazetto IA, Lee TC, Rollins IS, et al. Treatment of choroidal melanoma using photodynamic therapy. Am J Ophthalmol 2003;135:898–899.
31.Stephan H, Boeloeni R, Eggert A, et al. Photodynamic therapy in retinoblastoma: effects of verteporfin on retinoblastoma cell lines. Invest Ophthalmol Vis Sci 2008 Jul;49(7):3158–3163.
32.Sears KS, Rundle PR, Mudhar HS, et al. The effects of photodynamic therapy on conjunctival in situ squamous cell carcinoma – a review of the histopathology. Br J Ophthalmol 2008 May;92(5):716–717.
33.Yoon KC, You IC, Kang IS, et al. Photodynamic therapy with verteporfin for corneal neovascularization. Am J Ophthalmol 2007 Sep;144(3):
390–395.
34.Parodi MB, Iacono P, Ravalico G. Verteporfin photodynamic therapy for anterior segment neovascularization secondary to ischaemic central retinal vein occlusion. Clin Experiment Ophthalmol 2008 Apr;36(3):232–237.
35.Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419–1431.
36.Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S, ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006 Oct 5;355(14):1432–1444.
37.Azab M, Benchaboune M, Blinder KJ, et al. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: meta-analysis of 2-year safety results in three randomized clinical trials: treatment of age-related macular degeneration with photodynamic therapy and verteporfin in photodynamic therapy study report no. 4. Retina 2004 Feb;24(1):1–12.
38.Chang LK, Flaxel CJ, Lauer AK, Sarraf D. RPE tears after pegaptanib treatment in age-related macular degeneration. Retina 2007 Sep;27(7): 857–863.
39.QLT Inc. Clinical Investigator’s Brochure. BPD-MA (verteporfin). 2003 (Data on File).
Diseases Retinal in Mechanisms and Drugs • 4 section
305